SOTIO Biotech a.s.

2 trials 1 recruiting Commercial sponsor Merged from 2 name variants

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

4 Countries active

7 Unique IMPs

100% Results reported

Phase I

Phase I (FiH)

Phase I: 1 Phase I (FiH): 1

Oversight events:

4 temporary halts 1 urgent safety measure across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

FLUOROURACIL 1 FOLINIC ACID 1 GEMCITABINE 1 NIVOLUMAB 1 OXALIPLATIN 1 PACLITAXEL ALBUMIN-BOUND 1 SOT102 1

All trials

2 total

A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer Recruiting

2023-504330-21-00 Phase I 3 countries
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Ended

2023-504441-31-00 Phase I (FiH) 4 countries FLUOROURACIL; FOLINIC ACID; GEMCITABINE; NIVOLUMAB; OXALIPLATIN; PACLITAXEL ALBU…

Showing 1–2 of 2 trials

← All sponsors A–Z